Skip to main content

Advertisement

SpringerLink
Log in

Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials

  • REVIEW
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

We performed a systematic review and meta-analysis of randomized clinical trials. Early administration of bisphosphonates (BPs) after surgery did not appear to delay fracture healing time either radiologically or clinically. Furthermore, the anti-resorptive efficacy of BPs given immediately after surgical repair should positively affect the rate of subsequent fractures.

Introduction

Bisphosphonates (BPs) are widely used in the prophylaxis and treatment of osteoporosis. However, early administration of BPs after surgical repair of a fracture may limit the reserve capacity of bone to heal. The aim of this review and meta-analysis was to analyze the benefits and adverse effects of early administration of BPs and give recommendations regarding when BPs should be utilized.

Methods

We identified randomized controlled trials comparing the early administration of BPs to placebo, delayed BP treatment, or no therapy in adult patients after surgery. The search was performed in PubMed, the Cochrane Library, and Embase.

Results

Ten studies with 2888 patients were included. Four trials used alendronate, three trials used zoledronic, two trials used risedronate, and one trial used etidronate. Early administration of BPs was considered less than 3 months after surgery. Patients treated with BP therapy had no significant differences in radiological fracture healing times compared with patients in the control group (mean difference [MD] 0.47, 95 % confidence interval [CI] −2.75 to 3.69). There were also no significant differences in the rate of delay or nonunion of fracture healing (odds ratio [OR] 0.98, 95 % CI 0.64 to 1.50). However, the bone mineral density (BMD) of total hips did significantly improve after 12 months of treatment with BPs. And most bone turnover markers of patients in the study group were significantly decreased.

Conclusions

Early administration of BPs after surgery did not appear to delay fracture healing time either radiologically or clinically. Furthermore, according to the changes in BMD and bone turnover markers, the anti-resorptive efficacy of BPs given immediately after surgical repair should positively affect the rate of subsequent fractures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Giusti A, Hamdy NA, Papapoulos SE (2010) Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 47(2):169–180. doi:10.1016/j.bone.2010.05.019

    Article  CAS  PubMed  Google Scholar 

  2. Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS (2010) Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol 72(2):161–168. doi:10.1111/j.1365-2265.2009.03581.x

    Article  CAS  Google Scholar 

  3. Ha YC, Cho MR, Park KH, Kim SY, Koo KH (2010) Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Clin Orthop Relat Res 468(12):3393–3398. doi:10.1007/s11999-010-1583-2

    Article  PubMed Central  PubMed  Google Scholar 

  4. Weil YA, Rivkin G, Safran O, Liebergall M, Foldes AJ (2011) The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma 71(1):186–190. doi:10.1097/TA.0b013e31821957e3

    Article  CAS  PubMed  Google Scholar 

  5. von Knoch F, Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I, Rubash HE, Shanbhag AS (2005) Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 26(34):6941–6949. doi:10.1016/j.biomaterials.2005.04.059

    Article  Google Scholar 

  6. Li H, Xie H, Liu W, Hu R, Huang B, Tan YF, Xu K, Sheng ZF, Zhou HD, Wu XP, Luo XH (2009) A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. J Clin Invest 119(12):3666–3677. doi:10.1172/JCI39832

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Hu R, Liu W, Li H, Yang L, Chen C, Xia ZY, Guo LJ, Xie H, Zhou HD, Wu XP, Luo XH (2011) A Runx2/miR-3960/miR-2861 regulatory feedback loop during mouse osteoblast differentiation. J Biol Chem 286(14):12328–12339. doi:10.1074/jbc.M110.176099

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Shah A, Ahmad A (2011) Role of microRNA in mesenchymal stem cells differentiation into osteoblasts. Exp Hematol 39(6):608–616. doi:10.1016/j.exphem.2011.01.011

    Article  Google Scholar 

  9. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90(3):1294–1301. doi:10.1210/jc.2004-0952

    Article  CAS  PubMed  Google Scholar 

  10. Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, Akiyama T, Shi L, Komatsubara S, Miyamoto K, Norimatsu H (2002) Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res: Off J Am Soc Bone Miner Res 17(12):2237–2246. doi:10.1359/jbmr.2002.17.12.2237

    Article  CAS  Google Scholar 

  11. Matos MA, Tannuri U, Guarniero R (2010) The effect of zoledronate during bone healing. J Orthop Traumatol: Off J Italian Soc Orthop Traumatol 11(1):7–12. doi:10.1007/s10195-010-0083-1

    Article  Google Scholar 

  12. Li J, Mori S, Kaji Y, Mashiba T, Kawanishi J, Norimatsu H (1999) Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res: Off J Am Soc Bone Miner Res 14(6):969–979. doi:10.1359/jbmr.1999.14.6.969

    Article  CAS  Google Scholar 

  13. Li C, Mori S, Li J, Kaji Y, Akiyama T, Kawanishi J, Norimatsu H (2001) Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res: Off J Am Soc Bone Miner Res 16(3):429–436. doi:10.1359/jbmr.2001.16.3.429

    Article  CAS  Google Scholar 

  14. Bauss F, Schenk RK, Hort S, Muller-Beckmann B, Sponer G (2004) New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate. J Pharmacol Toxicol Methods 50(1):25–34. doi:10.1016/j.vascn.2003.11.003

    Article  CAS  PubMed  Google Scholar 

  15. Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH (2004) Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res: Off J Am Soc Bone Miner Res 19(11):1779–1786. doi:10.1359/JBMR.040814

    Article  CAS  Google Scholar 

  16. Greiner SH, Wildemann B, Back DA, Alidoust M, Schwabe P, Haas NP, Schmidmaier G (2008) Local application of zoledronic acid incorporated in a poly(D, L-lactide)-coated implant accelerates fracture healing in rats. Acta Orthop 79(5):717–725. doi:10.1080/17453670810016768

    Article  PubMed  Google Scholar 

  17. Rozental TD, Vazquez MA, Chacko AT, Ayogu N, Bouxsein ML (2009) Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg 34(4):595–602. doi:10.1016/j.jhsa.2008.12.011

    Article  Google Scholar 

  18. Amanat N, Brown R, Bilston LE, Little DG (2005) A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J Orthop Res: Off Publ Orthop Res Soc 23(5):1029–1034. doi:10.1016/j.orthres.2005.03.004

    Article  CAS  Google Scholar 

  19. Goodship AE, Walker PC, McNally D, Chambers T, Green JR (1994) Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. Ann Oncol 5(Suppl 7):S53–S55

    PubMed  Google Scholar 

  20. Little DG, McDonald M, Bransford R, Godfrey CB, Amanat N (2005) Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res: Off J Am Soc Bone Miner Res 20(11):2044–2052. doi:10.1359/JBMR.050712

    Article  CAS  Google Scholar 

  21. Bransford R, Goergens E, Briody J, Amanat N, Cree A, Little D (2007) Effect of zoledronic acid in an L6-L7 rabbit spine fusion model. Eur Spine J: Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Section Cervical Spine Res Soc 16(4):557–562. doi:10.1007/s00586-006-0212-y

    Article  Google Scholar 

  22. Grady MK, Watson JT, Cannada LK (2012) Treatment of femoral fracture nonunion after long-term bisphosphonate use. Orthopedics 35(6):e991–e995. doi:10.3928/01477447-20120525-51

    Article  PubMed  Google Scholar 

  23. Benlebna F, El AF, Boumediene ZB, El KM, Medghar S, Djaroud Z (2011) Delay of consolidation and bisphosphonates: two cases. Ann Phys Rehabil Med 54:e182–e183

    Article  Google Scholar 

  24. Czerwinski E, Osieleniec J, Loranc A (2011) Delayed union after atypical subtrochanteric fracture under alendronate treatment: case report. Osteoporos Int 22:S220

    Article  Google Scholar 

  25. Li C, Wang HR, Li XL, Zhou XG, Dong J (2012) The relation between zoledronic acid infusion and interbody fusion in patients undergoing transforaminal lumbar interbody fusion surgery. Acta Neurochir (Wien) 154(4):731–738. doi:10.1007/s00701-012-1283-7

    Article  Google Scholar 

  26. Colon-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, Mesenbrink P, Magaziner J, Adachi J, Lyles KW, Hyldstrup L, Bucci-Rechtweg C, Recknor C (2011) Association between timing of zoledronic acid infusion and hip fracture healing, vol 22. Osteoporos Int. doi:10.1007/s00198-010-1473-1

    Google Scholar 

  27. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, Trial HRF (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799–1809. doi:10.1056/NEJMoa074941

    Article  CAS  PubMed  Google Scholar 

  28. Ng AJ, Yue B, Joseph S, Richardson M (2014) Delayed/non-union of upper limb fractures with bisphosphonates: systematic review and recommendations. ANZ J Surg 84(4):218–224. doi:10.1111/ans.12536

    Article  PubMed  Google Scholar 

  29. Uchiyama S, Itsubo T, Nakamura K, Fujinaga Y, Sato N, Imaeda T, Kadoya M, Kato H (2013) Effect of early administration of alendronate after surgery for distal radial fragility fracture on radiological fracture healing time. Bone Joint J 95-B(11):1544–1550. doi:10.1302/0301-620x.95b11.31652

    Article  CAS  PubMed  Google Scholar 

  30. Kim TY, Ha YC, Kang BJ, Lee YK, Koo KH (2012) Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures? J Bone Joint Surg Br Vol 94:956–960. doi:10.1302/0301-620x.94b7.29079

    Article  Google Scholar 

  31. Gong HS, Song CH, Lee YH, Rhee SH, Lee HJ, Baek GH (2012) Early initiation of bisphosphonate does not affect healing and outcomes of volar plate fixation of osteoporotic distal radial fractures, vol 94. J Bone Joint Surg Am Vol. doi:10.2106/jbjs.k.01434

    Google Scholar 

  32. Harding AK, W-Dahl A, Geijer M, Toksvig-Larsen S, Tagil M (2011) A single bisphosphonate infusion does not accelerate fracture healing in high tibial osteotomies. Acta Orthop 82(4):465–470. doi:10.3109/17453674.2011.594231

    Article  PubMed Central  PubMed  Google Scholar 

  33. Harding AK, Toksvig-Larsen S, Tagil M, W-Dahl A (2010) A single dose zoledronic acid enhances pin fixation in high tibial osteotomy using the hemicallotasis technique. A double-blind placebo controlled randomized study in 46 patients. Bone 46(3):649–654. doi:10.1016/j.bone.2009.10.040

    Article  CAS  PubMed  Google Scholar 

  34. Cecilia D, Jodar E, Fernandez C, Resines C, Hawkins F (2009) Effect of alendronate in elderly patients after low trauma hip fracture repair. Osteoporos Int 20(6):903–910. doi:10.1007/s00198-008-0767-z

    Article  CAS  PubMed  Google Scholar 

  35. Altintas F, Ozkut AT, Beyzadeoglu T, Eren A, Guven M (2007) The effect of risedronate treatment on bone turnover markers in patients with hip fracture. Acta Orthop Traumatol Turc 41(2):132–135

    PubMed  Google Scholar 

  36. Sato Y, Kanoko T, Yasuda H, Satoh K, Iwamoto J (2004) Beneficial effect of etidronate therapy in immobilized hip fracture patients. Am J Phys Med Rehabil 83(4):298–303. doi:10.1097/01.PHM.0000122877.28631.23

    Article  PubMed  Google Scholar 

  37. van der Poest CE, van Engeland M, Ader H, Roos JC, Patka P, Lips P (2002) Alendronate in the prevention of bone loss after a fracture of the lower leg. J Bone Miner Res 17(12):2247–2255. doi:10.1359/jbmr.2002.17.12.2247

    Article  Google Scholar 

  38. Boonen S, Orwoll E, Magaziner J, Colon-Emeric CS, Adachi JD, Bucci-Rechtweg C, Haentjens P, Kaufman JM, Rizzoli R, Vanderschueren D, Claessens F, Sermon A, Witvrouw R, Milisen K, Su G, Lyles KW (2011) Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc 59(11):2084–2090. doi:10.1111/j.1532-5415.2011.03666.x

    Article  PubMed  Google Scholar 

  39. Adachi JD, Lyles K, Boonen S, Colon-Emeric C, Hyldstrup L, Nordsletten L, Pieper C, Recknor C, Su G, Bucci-Rechtweg C, Magaziner J (2011) Subtrochanteric fractures in bisphosphonate-naive patients: results from the HORIZON-Recurrent Fracture Trial. Calcif Tissue Int 89(6):427–433. doi:10.1007/s00223-011-9543-8

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Colon-Emeric CS, Lyles KW, Su G, Pieper CF, Magaziner JS, Adachi JD, Bucci-Rechtweg CM, Haentjens P, Boonen S (2011) Clinical risk factors for recurrent fracture after hip fracture: a prospective study. Calcif Tissue Int 88(5):425–431. doi:10.1007/s00223-011-9474-4

    Article  CAS  PubMed  Google Scholar 

  41. Adachi JD, Lyles KW, Colon-Emeric CS, Boonen S, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Bucci-Rechtweg C, Su G, Eriksen EF, Magaziner JS (2011) Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial. Osteoporos Int 22(9):2539–2549. doi:10.1007/s00198-010-1514-9

    Article  CAS  PubMed  Google Scholar 

  42. Colon-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, Mesenbrink P, Magaziner J, Adachi J, Lyles KW, Hyldstrup L, Bucci-Rechtweg C, Recknor C (2011) Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int 22(8):2329–2336. doi:10.1007/s00198-010-1473-1

    Article  CAS  PubMed  Google Scholar 

  43. Boonen S, Black DM, Colon-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, Lyles KW (2010) Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 58(2):292–299. doi:10.1111/j.1532-5415.2009.02673.x

    Article  PubMed Central  PubMed  Google Scholar 

  44. Colon-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25(1):91–97. doi:10.1359/jbmr.090704

    Article  CAS  PubMed  Google Scholar 

  45. Eriksen EF, Lyles KW, Colon-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, Mesenbrink P (2009) Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 24(7):1308–1313. doi:10.1359/jbmr.090209

    Article  CAS  PubMed  Google Scholar 

  46. Colon-Emeric CS, Caminis J, Suh TT, Pieper CF, Janning C, Magaziner J, Adachi J, Rosario-Jansen T, Mesenbrink P, Horowitz ZD, Lyles KW (2004) The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Curr Med Res Opin 20(6):903–910. doi:10.1185/030079904125003683

    Article  PubMed  Google Scholar 

  47. Moroni A, Faldini C, Hoang-Kim A, Pegreffi F, Giannini S (2007) Alendronate improves screw fixation in osteoporotic bone. J Bone Joint Surg Am 89(1):96–101. doi:10.2106/jbjs.f.00484

    Article  PubMed  Google Scholar 

  48. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 97(7):2272–2282. doi:10.1210/jc.2012-1027

    Article  CAS  PubMed  Google Scholar 

  49. Goldhahn J, Feron JM, Kanis J, Papapoulos S, Reginster JY, Rizzoli R, Dere W, Mitlak B, Tsouderos Y, Boonen S (2012) Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int 90(5):343–353. doi:10.1007/s00223-012-9587-4

    Article  CAS  PubMed  Google Scholar 

  50. Jorgensen NR, Schwarz P (2011) Effects of anti-osteoporosis medications on fracture healing. Curr Osteoporos Rep 9(3):149–155. doi:10.1007/s11914-011-0065-0

    Article  PubMed  Google Scholar 

  51. Miller PD (2005) Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep 3(3):103–110. doi:10.1007/s11914-005-0018-6

    Article  PubMed  Google Scholar 

  52. Coates P (2013) Bone turnover markers. Aust Fam Physician 42(5):285–287

    PubMed  Google Scholar 

  53. Klemens AS, McMillin DR (1990) New method for removing type 2 copper from Rhus laccase. J Inorg Biochem 38(2):107–115. doi:10.1016/0162-0134(90)84019-L

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Osteoporosis and Bone Disease, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University, Shanghai, 200233, China

    Y.-T. Li, H.-F. Cai & Z.-L. Zhang

Authors
  1. Y.-T. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H.-F. Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z.-L. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Z.-L. Zhang.

Additional information

Yi-Ting Li and Hai-Feng Cai contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, YT., Cai, HF. & Zhang, ZL. Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 26, 431–441 (2015). https://doi.org/10.1007/s00198-014-2903-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-014-2903-2

Keywords

Search

Navigation